


AMENDMENTS TO THE CLAIMS

Claims 1-10 (Canceled)

11. (Currently amended) A method for preventing or treating diseases accompanied by a decrease in bone weight in a mammal comprising increasing bone breaking load and strength in said mammal by administering to said mammal at least one member selected from the compound represented by Formula (1) or a multimer thereof from about 0.1 mg per day to about 20 mg per kg per day:



wherein A and B are the same or different and are independently selected from the group consisting of halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, phosphate, carboxy, hydroxy C₁-C₅ alkyl, sugar residue, -OR¹, and -OCOR²;

wherein R¹ is selected from the group consisting of hydrogen, C₁-C₅ alkyl, hydroxy C₁-C₅ alkyl, and C₂-C₅ alkenyl; and


R² is selected from the group consisting of C₁-C₅ alkyl, hydroxy C₁-C₅ alkyl, and C₂-C₅ alkenyl;

n is number of substituents A present and is a number from 0 to 5; and

m is number of substituents B present and is a number from 0 to 5.

Claims 12-18 (Canceled)

19. (Currently amended) A method for preventing cerebral apoplexy in a mammal, comprising administering to said mammal a composition comprising an effective amount of at least one member selected from the compound represented by Formula (1) or a multimer thereof from about 0.1 mg per day to about 20 mg per kg per day:



wherein A and B are the same or different and are independently selected from the group consisting of halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, phosphate, carboxy, hydroxy C₁-C₅ alkyl, sugar residue, -OR¹, and -OCOR²;

wherein R¹ is selected from the group consisting of hydrogen, C₁-C₅ alkyl, hydroxy C₁-C₅ alkyl, and C₂-C₅ alkenyl; and

R² is selected from the group consisting of C₁-C₅ alkyl, hydroxy C₁-C₅ alkyl, and C₂-C₅ alkenyl;

n is number of substituents A present and is a number from 0 to 5; and

m is number of substituents B present and is a number from 0 to 5;

wherein said composition does not contain ethanol.

20. (Previously presented) The method according to Claim 11, wherein the disease accompanied by a decrease in bone weight is any of menopausal or postmenopausal diseases.

21. (Previously presented) The method according to Claim 11, wherein said compound is part of a pharmaceutical formulation.

22. (Previously presented) The method according to Claim 11, wherein said compound is part of a food product.

23. (Previously presented) The method according to Claim 11, wherein the disease accompanied by a decrease in bone weight is a disease accompanied by resorption of alveolar bone.

24. (Previously presented) The method according to Claim 23, wherein said compound is adapted for oral administration performed by a medium selected from the group consisting of dentifrice, liquid dentifrice, mouthwash, mouth spray, oral liniment, swab, and floss.

25. (Previously presented) The method according to Claim 11, wherein the compound represented by Formula (1) is obtained from at least one plant selected from the group consisting of plants of Polygonaceae family, plants of Vitaceae family, white hellebore (*Veratrum album*), mulberry, and peanut.

Appl. No. : 09/890,416
Filed : July 27, 2001

26. (Previously presented) The method according to Claim 19, wherein said compound is part of a pharmaceutical formulation.

27. (Previously presented) The method according to Claim 19, wherein said compound is part of a food product.

28. (Previously presented) The method according to Claim 19, wherein cerebral apoplexy is present in menopausal or post-menopausal period.

29. (Previously presented) The method according to Claim 19, wherein the compound represented by Formula (1) is obtained from at least one plant selected from the group consisting of plants of Polygonaceae family, plants of Vitaceae family, white hellebore (*Veratrum album*), mulberry, and peanut.